FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
This article was originally published in Pharmaceutical Approvals Monthly
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
You may also be interested in...
Announcing the PDUFA fees for fiscal 2011, agency says it expects to receive 117.5 fee-paying full application equivalents in the current fiscal year, down 16 percent from the 2009 level.
Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class